# Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

> **NCT05371132** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 10 (estimated)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Lymphoma

## Interventions

- **PROCEDURE:** Positron Emission Tomography
- **RADIATION:** Stereotactic Body Radiation Therapy
- **DRUG:** Zirconium Zr 89-Df-Crefmirlimab
- **RADIATION:** Intensity Modulated Radiation Therapy

## Key facts

- **NCT ID:** NCT05371132
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2026-10-05
- **Final completion:** 2026-10-05
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05371132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05371132, "Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05371132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*